Promius Pharma, LLC
10
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
20.0%
2 terminated/withdrawn out of 10 trials
80.0%
-6.5% vs industry average
70%
7 trials in Phase 3/4
100%
8 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp
Role: lead
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Role: lead
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
Role: lead
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
Role: lead
Promiseb Topical Cream for Cradle Cap
Role: lead
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis
Role: lead
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Role: lead
Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
Role: lead
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
Role: lead
Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
Role: lead
All 10 trials loaded